Literature DB >> 7545770

Treatment of schizophrenia.

J M Kane1, T H McGlashan.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7545770     DOI: 10.1016/s0140-6736(95)91630-x

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  14 in total

Review 1.  Fortnightly review. Treatment of schizophrenia.

Authors:  J McGrath; W B Emmerson
Journal:  BMJ       Date:  1999-10-16

Review 2.  Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis.

Authors:  J Geddes; N Freemantle; P Harrison; P Bebbington
Journal:  BMJ       Date:  2000-12-02

Review 3.  Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia.

Authors:  Jiri Horacek; Vera Bubenikova-Valesova; Milan Kopecek; Tomas Palenicek; Colleen Dockery; Pavel Mohr; Cyril Höschl
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 4.  State of the science on psychosocial interventions for ethnic minorities.

Authors:  Jeanne Miranda; Guillermo Bernal; Anna Lau; Laura Kohn; Wei-Chin Hwang; Teresa LaFromboise
Journal:  Annu Rev Clin Psychol       Date:  2005       Impact factor: 18.561

5.  Management of schizophrenia : an update.

Authors:  P Kulhara
Journal:  Indian J Psychiatry       Date:  1998-04       Impact factor: 1.759

Review 6.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

7.  Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial.

Authors:  S H Hamilton; D A Revicki; E T Edgell; L A Genduso; G Tollefson
Journal:  Pharmacoeconomics       Date:  1999-05       Impact factor: 4.981

8.  Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs.

Authors:  D E Adkins; K Aberg; J L McClay; J Bukszár; Z Zhao; P Jia; T S Stroup; D Perkins; J P McEvoy; J A Lieberman; P F Sullivan; E J C G van den Oord
Journal:  Mol Psychiatry       Date:  2010-03-02       Impact factor: 15.992

9.  Analysis of West Virginia medicaid claims data for the prevalence of medical conditions and use of drugs likely to cause QT prolongation in patients with schizophrenia.

Authors:  Iftekhar D Kalsekar; Eugene H Makela; Karen E Moeller
Journal:  Curr Ther Res Clin Exp       Date:  2003-09

10.  Genome-wide association study of antipsychotic-induced QTc interval prolongation.

Authors:  K Aberg; D E Adkins; Y Liu; J L McClay; J Bukszár; P Jia; Z Zhao; D Perkins; T S Stroup; J A Lieberman; P F Sullivan; E J C G van den Oord
Journal:  Pharmacogenomics J       Date:  2010-10-05       Impact factor: 3.550

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.